Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- LZB +9.8%, PDCO +7.6%, CGNT +3.6%, DTE +1.2% (reaffirms guidance)
Other news:
- SILK +23.3% (to be acquired by Boston Scientific (BSX) for $27.50 per share in cash)
- CHGG +19.5% (restructuring plan)
- FLFV +18.1% (Announces Approval of Business Combination by Stockholders)
- RKLB +8.8% (Signs Record Deal for 10 Electron Launches with Synspective)
- TSHA +6.5% (announces positive clinical data across adult and pediatric patients from low dose cohort in ongoing REVEAL phase 1/2 trials evaluating TSHA-102 in rett syndrome)
- KROS +4.3% (CEO appointed Board Chair)
- AEIS +3.8% (announces no intention to make an offer for XP Power Limited)
- SIGA +3.1% (to expand access to TPOXX to ASEAN member states)
- CTMX +2.9% (names new CFO)
- IMCR +2.7% (announces randomization of the first patient in the PRISM-MEL-301 trial)
- AMCX +2.5% (prices offering of $125 mln of 4.25% convertible senior notes due 2029)
- PRCT +2.4% (AMA establishes new CPT Category I code)
- KALV +1.9% (submits New Drug Application to FDA for Sebetralstat)
- ATRO +1.8% (awarded contract for U.S. Army Radio Test Set TS-4549/T valued at ~$215 million)
- MRK +1.4% (FDA approves KEYTRUDA plus other medication; also approves CAPVAXIVE)
- ALIT +1.1% (announces $75 million accelerated share repurchase agreement)
- RGNX +1% (completed a successful Pre-Biologics License Application meeting for RGX-121 for the treatment Mucopolysaccharidosis Type II, where it finalized details of its BLA with the U.S. FDA)
- BBIO +1% (announces it has surpassed its interim analysis enrollment target and expects topline interim data from its Phase 3 registrational study in individuals with LGMD2I/R9 in 2025)